The two doses of the vaccine will be administered to those aged 16 years and above. Credit: Arne Müseler.

Australia’s Therapeutic Goods Administration (TGA) has provisionally approved the Pfizer–BioNTech Covid-19 vaccine for use in people aged 16 years and above.

The two doses of the vaccine will be administered at the scheduled time, Reuters reported.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The news agency quoted Australian Prime Minister Scott Morrison as saying that the country’s medical regulator was one of the first in the world to complete a comprehensive approval of the Pfizer-BioNTech vaccine.

Initially, priority groups will receive the vaccine, starting in late February, with plans to deliver 80,000 doses per week, Health Minister Greg Hunt said.

The country also warned that AstraZeneca’s international production issues could delay the distribution of a locally manufactured shot.

Meanwhile, Pfizer and BioNTech entered into an advance purchase agreement with COVAX to supply up to 40 million doses of their Covid-19 vaccine throughout this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pfizer chairman and CEO Albert Bourla said: “We share the mission of COVAX and are proud to work together so that developing countries have the same access as the rest of the world, which will bring us another step closer to ending this global pandemic and proving that Science Will Win for everyone, everywhere.”

Pfizer noted that the initial doses will be supplied in the first quarter of this year at a not-for-profit price.

Earlier this month, Colombia’s National Institute of Drug and Food Surveillance (INVIMA) authorised emergency use of the vaccine.

In a separate development, the Drug Regulatory Authority of Pakistan (DRAP) granted emergency use authorisation (EUA) to Russia’s Covid-19 vaccine, Sputnik V.

Separately, the Moroccan Ministry of Health authorised Chinese company Sinopharm’s Covid-19 vaccine for emergency use.